All In Biotech

Drug Trial Radar · NCT07093697

A Study to Evaluate the Efficacy and Safety of DW5121 Compared to DW51211 and DW51212

Phase III Clinical Trial to Evaluate the Efficacy and Safety of DW5121 Compared to DW51211 and DW51212

Last checked: Nov 19, 2026Latest source record: Jul 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 273 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

273

Actual

Start

Mar 28, 2024

Primary completion

May 27, 2025

Study completion May 27, 2025

Sponsor

Sponsor type
Industry
First posted
Jul 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, randomized, double-blind, active-controlled, parallel-group, multi-center clinical trial to evaluate the efficacy and safety of DW5121 compared to DW51211 and DW51212 in patients with acute bronchitis. The primary objective is to demonstrate the superiority of DW5121 over DW51211 and DW51212 by comparing the change in total Bronchitis Severity Score (BSS) at Day 4 after administration. Approximately equal numbers of patients were randomized in a 1:1:1 ratio to receive DW5121, DW51211, or DW51212 for 7 days. Efficacy and safety assessments were conducted at Day 4 and Day 7, with a follow-up contact approximately 5 days after the end of treatment to monitor adverse events.

Conditions

  • Acute Bronchitis

Interventions

  • DW5121Drug

    Participants receive DW5121, 2 tablets orally, DW51211 Placebo, 2 tablets orally, DW51212 Placebo, 1 tablets orally, 3 times a day after meals for 7 days

  • DW51211Drug

    Participants receive DW5121 placebo, 2 tablets orally, DW51211, 2 tablets orally, DW51212 Placebo, 1 tablets orally, 3 times a day after meals for 7 days

  • DW51212Drug

    Participants receive DW5121 placebo, 2 tablets orally, DW51211 placebo, 2 tablets orally, DW51212 , 1 tablets orally, 3 times a day after meals for 7 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Bronchitis Severity Score (BSS) total score at Day 4 after dosingTime frame: Day 4 after first dose

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Soonchunhyang University Bucheon Hospital

    Bucheon-si, South Korea

  • Hallym University Chuncheon Sacred Heart Hospital

    Chuncheon, South Korea

  • Yeungnam University Medical Center

    Daegu, South Korea

  • Wonkwang University Hospital

    Iksan, South Korea

  • Kangbuk Samsung Hospital

    Seoul, South Korea

  • Konkuk University Medical Center

    Seoul, South Korea

  • Hallym University Kangdong Sacred Heart Hospital

    Seoul, South Korea

  • Korea University Guro Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.